|
1
|
Dameshek W: Some speculations on the
myeloproliferative syndromes. Blood. 6:372–375. 1951. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fialkow PJ, Gartler SM and Yoshida A:
Clonal origin of chronic myelocytic leukemia in man. Proc Natl Acad
Sci USA. 58:1468–1471. 1967. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tefferi A: The history of
myeloproliferative disorders: Before and after dameshek. Leukemia.
22:3–13. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Moulard O, Mehta J, Fryzek J, Olivares R,
Iqbal U and Mesa RA: Epidemiology of myelofibrosis, essential
thrombocythemia, and polycythemia vera in the European union. Eur J
Haematol. 92:289–297. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mehta J, Wang H, Iqbal SU and Mesa R:
Epidemiology of myeloproliferative neoplasms in the United States.
Leuk Lymphoma. 55:595–600. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Baxter EJ, Scott LM, Campbell PJ, East C,
Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N,
et al: Acquired mutation of the tyrosine kinase JAK2 in human
myeloproliferative disorders. Lancet. 365:1054–1061. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Levine RL, Wadleigh M, Cools J, Ebert BL,
Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, et
al: Activating mutation in the tyrosine kinase JAK2 in polycythemia
vera, essential thrombocythemia, and myeloid metaplasia with
myelofibrosis. Cancer Cell. 7:387–397. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
James C, Ugo V, Le Couedic JP, Staerk J,
Delhommeau F, Lacout C, Garçon L, Raslova H, Berger R,
Bennaceur-Griscelli A, et al: A unique clonal JAK2 mutation leading
to constitutive signalling causes polycythaemia vera. Nature.
434:1144–1148. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kralovics R, Passamonti F, Buser AS, Teo
SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M and Skoda RC: A
gain-of-function mutation of JAK2 in myeloproliferative disorders.
N Engl J Med. 352:1779–1790. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Scott LM, Tong W, Levine RL, Scott MA,
Beer PA, Stratton MR, Futreal PA, Erber WN, McMullin MF, Harrison
CN, et al: JAK2 exon 12 mutations in polycythemia vera and
idiopathic erythrocytosis. N Engl J Med. 356:459–468. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Silver RT, Chow W, Orazi A, Arles SP and
Goldsmith SJ: Evaluation of WHO criteria for diagnosis of
polycythemia vera: A prospective analysis. Blood. 122:1881–1886.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bandaranayake RM, Ungureanu D, Shan Y,
Shaw DE, Silvennoinen O and Hubbard SR: Crystal structures of the
JAK2 pseudokinase domain and the pathogenic mutant V617F. Nat
Struct Mol Biol. 19:754–759. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Saharinen P, Takaluoma K and Silvennoinen
O: Regulation of the Jak2 tyrosine kinase by its pseudokinase
domain. Mol Cell Biol. 20:3387–3395. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vainchenker W and Constantinescu SN:
JAK/STAT signaling in hematological malignancies. Oncogene.
32:2601–2613. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vainchenker W and Kralovics R: Genetic
basis and molecular pathophysiology of classical myeloproliferative
neoplasms. Blood. 129:667–679. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Neubauer H, Cumano A, Muller M, Wu H,
Huffstadt U and Pfeffer K: Jak2 deficiency defines an essential
developmental checkpoint in definitive hematopoiesis. Cell.
93:397–409. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Staerk J and Constantinescu SN: The
JAK-STAT pathway and hematopoietic stem cells from the JAK2 V617F
perspective. JAKSTAT. 1:184–190. 2012.PubMed/NCBI
|
|
18
|
Parganas E, Wang D, Stravopodis D, Topham
DJ, Marine JC, Teglund S, Vanin EF, Bodner S, Colamonici OR, van
Deursen JM, et al: Jak2 is essential for signaling through a
variety of cytokine receptors. Cell. 93:385–395. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
de Freitas RM and da Costa Maranduba CM:
Myeloproliferative neoplasms and the JAK/STAT signaling pathway: An
overview. Rev Bras Hematol Hemoter. 37:348–353. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Barbui T, Thiele J, Gisslinger H,
Kvasnicka HM, Vannucchi AM, Guglielmelli P, Orazi A and Tefferi A:
The 2016 WHO classification and diagnostic criteria for
myeloproliferative neoplasms: Document summary and in-depth
discussion. Blood Cancer J. 8:152018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tefferi A: Novel mutations and their
functional and clinical relevance in myeloproliferative neoplasms:
JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 24:1128–1138.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Carvalho BS and Irizarry RA: A framework
for oligonucleotide microarray preprocessing. Bioinformatics.
26:2363–2367. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Team RC: R: A Language and Environment for
Statistical Computing. R Foundation for Statistical Computing;
Vienna, Austria: 2012
|
|
24
|
Huang da W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Huang da W, Sherman BT and Lempicki RA:
Bioinformatics enrichment tools: Paths toward the comprehensive
functional analysis of large gene lists. Nucleic Acids Res.
37:1–13. 2009. View Article : Google Scholar
|
|
26
|
Szklarczyk D, Gable AL, Lyon D, Junge A,
Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork
P, et al: STRING v11: Protein-protein association networks with
increased coverage, supporting functional discovery in genome-wide
experimental datasets. Nucleic Acids Res. 47(D1):D607–D613. 2019.
View Article : Google Scholar
|
|
27
|
Pinto JP, Kalathur RK, Oliveira DV, Barata
T, Machado RS, Machado S, Pacheco-Leyva I, Duarte I and Futschik
ME: StemChecker: A web-based tool to discover and explore stemness
signatures in gene sets. Nucleic Acids Res. 43:W72–W77. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Metsalu T and Vilo J: ClustVis: A web tool
for visualizing clustering of multivariate data using principal
component analysis and heatmap. Nucleic Acids Res. 43:W566–W570.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cilloni D and Saglio G: Molecular
pathways: BCR-ABL. Clin Cancer Res. 18:930–937. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Peters AH, O'Carroll D, Scherthan H,
Mechtler K, Sauer S, Schöfer C, Weipoltshammer K, Pagani M, Lachner
M, Kohlmaier A, et al: Loss of the Suv39h histone
methyltransferases impairs mammalian heterochromatin and genome
stability. Cell. 107:323–337. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Schaniel C, Ang YS, Ratnakumar K, Cormier
C, James T, Bernstein E, Lemischka IR and Paddison PJ:
Smarcc1/Baf155 couples self-renewal gene repression with changes in
chromatin structure in mouse embryonic stem cells. Stem Cells.
27:2979–2991. 2009.PubMed/NCBI
|
|
33
|
Goldman SL, Hassan C, Khunte M, Soldatenko
A, Jong Y, Afshinnekoo E and Mason CE: Epigenetic modifications in
acute myeloid leukemia: Prognosis, treatment, and heterogeneity.
Front Genet. 10:1332019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lim WF, Inoue-Yokoo T, Tan KS, Lai MI and
Sugiyama D: Hematopoietic cell differentiation from embryonic and
induced pluripotent stem cells. Stem Cell Res Ther. 4:712013.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Blum B and Benvenisty N: The
tumorigenicity of human embryonic stem cells. Adv Cancer Res.
100:133–158. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lambert M, Jambon S, Depauw S and
David-Cordonnier MH: Targeting transcription factors for cancer
treatment. Molecules. 23:14792018. View Article : Google Scholar
|
|
37
|
Boyer LA, Lee TI, Cole MF, Johnstone SE,
Levine SS, Zucker JP, Guenther MG, Kumar RM, Murray HL, Jenner RG,
et al: Core transcriptional regulatory circuitry in human embryonic
stem cells. Cell. 122:947–956. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hsu J and Sage J: Novel functions for the
transcription factor E2F4 in development and disease. Cell Cycle.
15:3183–3190. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gawlik-Rzemieniewska N and Bednarek I: The
role of NANOG transcriptional factor in the development of
malignant phenotype of cancer cells. Cancer Biol Ther. 17:1–10.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Son HJ, Kim JY, Hahn Y and Seo SB:
Negative regulation of JAK2 by H3K9 methyltransferase G9a in
leukemia. Mol Cell Biol. 32:3681–3694. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sidney LE, Branch MJ, Dunphy SE, Dua HS
and Hopkinson A: Concise review: Evidence for CD34 as a common
marker for diverse progenitors. Stem Cells. 32:1380–1389. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shammo JM and Stein BL: Mutations in MPNs:
Prognostic implications, window to biology, and impact on treatment
decisions. Hematology Am Soc Hematol Educ Program. 2016:552–560.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mead AJ and Mullally A: Myeloproliferative
neoplasm stem cells. Blood. 129:1607–1616. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Aleem E and Arceci RJ: Targeting cell
cycle regulators in hematologic malignancies. Front Cell Dev Biol.
3:162015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Bertoli C, Skotheim JM and de Bruin RA:
Control of cell cycle transcription during G1 and S phases. Nat Rev
Mol Cell Biol. 14:518–528. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Werwein E, Cibis H, Hess D and Klempnauer
KH: Activation of the oncogenic transcription factor B-Myb via
multisite phosphorylation and prolyl cis/trans isomerization.
Nucleic Acids Res. 47:103–121. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Koseoglu MM, Dong J and Marzluff WF:
Coordinate regulation of histone mRNA metabolism and DNA
replication: Cyclin A/cdk1 is involved in inactivation of histone
mRNA metabolism and DNA replication at the end of S phase. Cell
Cycle. 9:3857–3863. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zeng X, Chen S and Huang H:
Phosphorylation of EZH2 by CDK1 and CDK2: A possible regulatory
mechanism of transmission of the H3K27me3 epigenetic mark through
cell divisions. Cell Cycle. 10:579–583. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Yu Z, Zhou X, Wang W, Deng W, Fang J, Hu
H, Wang Z, Li S, Cui L, Shen J, et al: Dynamic phosphorylation of
CENP-A at Ser68 orchestrates its cell-cycle-dependent deposition at
centromeres. Dev Cell. 32:68–81. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Jiang PS, Chang JH and Yung BY: Different
kinases phosphorylate nucleophosmin/B23 at different sites during
G(2) and M phases of the cell cycle. Cancer Lett. 153:151–160.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Monte M, Benetti R, Buscemi G, Sandy P,
Del Sal G and Schneider C: The cell cycle-regulated protein human
GTSE-1 controls DNA damage-induced apoptosis by affecting p53
function. J Biol Chem. 278:30356–30364. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
McPherson S, McMullin MF and Mills K:
Epigenetics in myeloproliferative neoplasms. J Cell Mol Med.
21:1660–1667. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Black JC, Van Rechem C and Whetstine JR:
Histone lysine methylation dynamics: Establishment, regulation, and
biological impact. Mol Cell. 48:491–507. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Nielsen HM, Andersen CL, Westman M,
Kristensen LS, Asmar F, Kruse TA, Thomassen M, Larsen TS, Skov V,
Hansen LL, et al: Publisher correction: Epigenetic changes in
myelofibrosis: Distinct methylation changes in the myeloid
compartments and in cases with ASXL1 mutations. Sci Rep.
8:173112018. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Mi W, Guan H, Lyu J, Zhao D, Xi Y, Jiang
S, Andrews FH, Wang X, Gagea M, Wen H, et al: YEATS2 links histone
acetylation to tumorigenesis of non-small cell lung cancer. Nat
Commun. 8:10882017. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Panagopoulos I, Micci F, Thorsen J,
Gorunova L, Eibak AM, Bjerkehagen B, Davidson B and Heim S: Novel
fusion of MYST/Esa1-associated factor 6 and PHF1 in endometrial
stromal sarcoma. PLoS One. 7:e393542012. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Battaglia S, Maguire O and Campbell MJ:
Transcription factor co-repressors in cancer biology: Roles and
targeting. Int J Cancer. 126:2511–2519. 2010.PubMed/NCBI
|
|
58
|
Viiri KM, Korkeamaki H, Kukkonen MK,
Nieminen LK, Lindfors K, Peterson P, Mäki M, Kainulainen H and Lohi
O: SAP30L interacts with members of the Sin3A corepressor complex
and targets Sin3A to the nucleolus. Nucleic Acids Res.
34:3288–3298. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
DeVilbiss AW, Boyer ME and Bresnick EH:
Establishing a hematopoietic genetic network through locus-specific
integration of chromatin regulators. Proc Natl Acad Sci USA.
110:E3398–3407. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Arteaga MF, Mikesch JH, Fung TK and So CW:
Epigenetics in acute promyelocytic leukaemia pathogenesis and
treatment response: A TRAnsition to targeted therapies. Br J
Cancer. 112:413–418. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Crepaldi L, Policarpi C, Coatti A,
Sherlock WT, Jongbloets BC, Down TA and Riccio A: Binding of TFIIIC
to sine elements controls the relocation of activity-dependent
neuronal genes to transcription factories. PLoS Genet.
9:e10036992013. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Malik P, Zuleger N, de las Heras JI,
Saiz-Ros N, Makarov AA, Lazou V, Meinke P, Waterfall M, Kelly DA
and Schirmer EC: NET23/STING promotes chromatin compaction from the
nuclear envelope. PLoS One. 9:e1118512014. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Thacker J and Zdzienicka MZ: The XRCC
genes: Expanding roles in DNA double-strand break repair. DNA
Repair (Amst). 3:1081–1090. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Spruijt CG, Gnerlich F, Smits AH,
Pfaffeneder T, Jansen PW, Bauer C, Münzel M, Wagner M, Müller M,
Khan F, et al: Dynamic readers for 5-(hydroxy)methylcytosine and
its oxidized derivatives. Cell. 152:1146–1159. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Krasteva V, Crabtree GR and Lessard JA:
The BAF45a/PHF10 subunit of SWI/SNF-like chromatin remodeling
complexes is essential for hematopoietic stem cell maintenance. Exp
Hematol. 48:58–71 e15. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Kadoch C and Crabtree GR: Reversible
disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic
fusion in synovial sarcoma. Cell. 153:71–85. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Pattabiraman DR and Gonda TJ: Role and
potential for therapeutic targeting of MYB in leukemia. Leukemia.
27:269–277. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Hu T, Chong Y, Cai B, Liu Y, Lu S and
Cowell JK: DNA methyltransferase 1-mediated CpG methylation of the
miR-150-5p promoter contributes to fibroblast growth factor
receptor 1-driven leukemogenesis. J Biol Chem. 294:18122–18130.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Griffiths DS, Li J, Dawson MA, Trotter MW,
Cheng YH, Smith AM, Mansfield W, Liu P, Kouzarides T, Nichols J, et
al: LIF-independent JAK signalling to chromatin in embryonic stem
cells uncovered from an adult stem cell disease. Nat Cell Biol.
13:13–21. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Langlois T, da Costa Reis Monte-Mor B,
Lenglet G, Droin N, Marty C, Le Couédic JP, Almire C, Auger N,
Mercher T, Delhommeau F, et al: TET2 deficiency inhibits mesoderm
and hematopoietic differentiation in human embryonic stem cells.
Stem Cells. 32:2084–2097. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Mascarenhas J, Sandy L, Lu M, Yoon J,
Petersen B, Zhang D, Ye F, Newsom C, Najfeld V, Hochman T, et al: A
phase II study of panobinostat in patients with primary
myelofibrosis (PMF) and post-polycythemia vera/essential
thrombocythemia myelofibrosis (post-PV/ET MF). Leuk Res. 53:13–19.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Rambaldi A, Dellacasa CM, Finazzi G,
Carobbio A, Ferrari ML, Guglielmelli P, Gattoni E, Salmoiraghi S,
Finazzi MC, Di Tollo S, et al: A pilot study of the
Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F
positive chronic myeloproliferative neoplasms. Br J Haematol.
150:446–455. 2010.PubMed/NCBI
|
|
73
|
Silverman LR, McKenzie DR, Peterson BL,
Holland JF, Backstrom JT, Beach CL and Larson RA; Cancer Leukemia
Group B, : Further analysis of trials with azacitidine in patients
with myelodysplastic syndrome: Studies 8421, 8921, and 9221 by the
cancer and leukemia Group B. J Clin Oncol. 24:3895–3903. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Kantarjian HM, O'Brien S, Huang X,
Garcia-Manero G, Ravandi F, Cortes J, Shan J, Davisson J,
Bueso-Ramos CE and Issa JP: Survival advantage with decitabine
versus intensive chemotherapy in patients with higher risk
myelodysplastic syndrome: Comparison with historical experience.
Cancer. 109:1133–1137. 2007. View Article : Google Scholar : PubMed/NCBI
|
